Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tadao Ishida

Showing results (61-70 of 151) with videos related to

Pageof 16
Sort By:
International Journal of Hematology|May 9, 2025
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MMShinsuke Iida, Kazutaka Sunami, Shigeki Ito, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 8, 2011
[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation]Toshiaki Hayashi, Hiroshi Yasui, Kentaro Kawakami, et al.
Modern Rheumatology|December 3, 2013
A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndromeTetsuya Tabeya, Toshiaki Sugaya, Chisako Suzuki, et al.
International Journal of Hematology|May 13, 2022
MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantationShinsuke Iida, Tadao Ishida, Toshihiro Miyamoto, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 9, 2025
[Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis]Kodai Kunisada, Mizuki Ogura, Yuki Oda, et al.
Cureus|December 25, 2023
Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based TreatmentTaku Kikuchi, Nobuhiro Tsukada, Yuki Oda, et al.
Internal Medicine (Tokyo, Japan)|August 4, 2015
Pericardial Effusion and Multiple Organ Involvement Are Independent Predictors of Mortality in Patients with Systemic Light Chain AmyloidosisSatoshi Yuda, Toshiaki Hayashi, Kenji Yasui, et al.
Annals of Hematology|April 28, 2023
Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatmentTaku Kikuchi, Nobuhiro Tsukada, Moe Nomura, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 7, 2020
[Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation]Kota Sato, Nobuhiro Tsukada, Junichiro Nashimoto, et al.
International Journal of Hematology|January 23, 2023
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myelomaDaisuke Minakata, Tadao Ishida, Kiyoshi Ando, et al.
Pageof 16

Showing results (61-70 of 151) with videos related to

Sort By:
Pageof 16
International Journal of Hematology|May 9, 2025
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MMShinsuke Iida, Kazutaka Sunami, Shigeki Ito, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 8, 2011
[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation]Toshiaki Hayashi, Hiroshi Yasui, Kentaro Kawakami, et al.
Modern Rheumatology|December 3, 2013
A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndromeTetsuya Tabeya, Toshiaki Sugaya, Chisako Suzuki, et al.
International Journal of Hematology|May 13, 2022
MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantationShinsuke Iida, Tadao Ishida, Toshihiro Miyamoto, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 9, 2025
[Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis]Kodai Kunisada, Mizuki Ogura, Yuki Oda, et al.
Cureus|December 25, 2023
Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based TreatmentTaku Kikuchi, Nobuhiro Tsukada, Yuki Oda, et al.
Internal Medicine (Tokyo, Japan)|August 4, 2015
Pericardial Effusion and Multiple Organ Involvement Are Independent Predictors of Mortality in Patients with Systemic Light Chain AmyloidosisSatoshi Yuda, Toshiaki Hayashi, Kenji Yasui, et al.
Annals of Hematology|April 28, 2023
Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatmentTaku Kikuchi, Nobuhiro Tsukada, Moe Nomura, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 7, 2020
[Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation]Kota Sato, Nobuhiro Tsukada, Junichiro Nashimoto, et al.
International Journal of Hematology|January 23, 2023
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myelomaDaisuke Minakata, Tadao Ishida, Kiyoshi Ando, et al.
Pageof 16